One in Three Alzheimer, Dementia Cases Tied to Modifiable Risk Factors

WEDNESDAY, May 11, 2022 (HealthDay News) -- Midlife obesity, physical inactivity, and low education are the three most prominent modifiable risk factors associated with Alzheimer disease and related dementias (ADRDs), according to a study published online May 9 in JAMA Neurology.
Roch A. Nianogo, M.D., Ph.D., from University of California in Los Angeles, and colleagues estimated the proportion of ADRDs in the United States that are associated with modifiable risk factors and assessed differences by sex and race and ethnicity. Risk factor prevalence were estimated from the 2018 U.S. Behavioral Risk Factor Surveillance Survey (378,615 individuals), while relative risks for each risk factor were extracted from meta-analyses.
The researchers found that approximately one in three ADRD cases (36.9 percent) were associated with eight modifiable risk factors, the most prominent of which were midlife obesity (17.7 percent), physical inactivity (11.8 percent), and low educational attainment (11.7 percent). Men had higher combined population-attributable risks than women (35.9 versus 30.1 percent), with differences also seen by race and ethnicity (American Indian and Alaska Native individuals, 39 percent; Asian individuals, 16 percent; Black individuals, 40 percent; Hispanic individuals [any race], 34 percent; White individuals, 29 percent).
"Alzheimer risk reduction strategies may be more effective if they target higher-risk groups and consider current risk factor profiles," the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Retired Olympians Face Higher Odds for Arthritis
WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- Olympic athletes aren't like the...
Unos datos muestran los dos principales factores del riesgo de cáncer
LUNES, 8 de agosto de 2022 (HealthDay News) -- Fumar y una edad más avanzada son...
Taken Prior to Sex, New Combo Pill May Prevent Pregnancy for Days
TUESDAY, April 26, 2022 (HealthDay News) -- Imagine a birth control pill a woman...
Axillary Lymphadenopathy Resolves at Mean 102 Days After COVID-19 Booster
WEDNESDAY, March 15, 2023 (HealthDay News) -- The time to resolution of axillary...